Start of human trials of COVID-19 vaccine candidate important milestone for Atmanirbhar Bharat: DBT

ZyCoV-D and COVAXIN are the only two vaccine candidates to have got a nod from the drug regulatory body to conduct human trials

Start of human trials of COVID-19 vaccine candidate important milestone for Atmanirbhar Bharat: DBT

New Delhi, July 16

Zydus Cadila’s move to begin human trials of its indigenously developed vaccine candidate for COVID-19 is an important milestone for an ‘Atmanirbhar Bharat’, Department of Biotechnology Secretary Renu Swarup said on Thursday.

Zydus Cadila on Wednesday said it has initiated Phase 1 and 2 clinical trials of its COVID-19 vaccine candidate. ZyCoV-D, the plasmid DNA vaccine designed and developed by Zydus, has been partially funded by the Department of Biotechnology under the National Biopharma Mission.

This makes it the first indigenously developed vaccine for COVID-19 to be administered in humans in the country, the DBT secretary said in a statement.

Swarup said the development is also a big leap forward for the scientific community.

“This is an important milestone for Atmanirbhar Bharat as Zydus begins human clinical trials for the indigenously developed vaccine. We hope that the vaccine continues to show positive outcomes as it has done so far in the pre-clinical phase where it was found to be safe, immunogenic and well-tolerated,” she said.

The adaptive phase 1 and 2 dose-escalation, the multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine, the statement said.

ZyCoV-D and COVAXIN, developed by city-based Bharat Biotech in collaboration with Indian Council of Medical Research, are the only two vaccine candidates to have got a nod from the drug regulatory body to conduct human trials.

“This partnership with Zydus is to serve the country's need for a vaccine to fight the dreaded pandemic which has put a billion people at risk,” Swarup said.

Such research endeavours will help the country develop preventive strategies for future disease outbreaks as well. They exemplify the government’s focus on creating an ecosystem that nurtures and encourages new product innovation to make real and measurable changes to issues most relevant to our society, Swarup added.

Zydus Cadila chairperson Pankaj Patel said the commencement of human trials is a very important step in the fight against the pandemic and one that will help the nation combat the healthcare challenge.

In the pre-clinical phase, the vaccine was found to elicit a strong immune response in multiple animal species such as mice, rats, guinea pigs and rabbits.

The antibodies produced by the vaccine were able to neutralise the wild type virus in virus neutralisation assay indicating the protective potential of the vaccine candidate.

No safety concerns were observed for the vaccine candidate in repeat-dose toxicology studies by both intramuscular and intradermal routes of administration. In rabbits, up to three times the intended human dose was found to be safe, well tolerated and immunogenic, the DBT statement added. PTI

Top Stories

Farmers' sit-in at Noida-Delhi border; key route to Delhi closed for vehicles

Farmers' sit-in at Noida-Delhi border; key route to Delhi closed for vehicles

The farmers at the Delhi-Noida border belong to various dist...

Sunny Deol tests Covid positive in Himachal’s Manali

Sunny Deol tests Covid positive in Himachal’s Manali

The 64-year-old Bollywood actor had undergone a shoulder sur...

National Covid recovery rate crosses 94 per cent

National Covid recovery rate crosses 94 per cent

Total cases almost 95 lakh

8 killed as truck overturns on car in UP

8 killed as truck overturns on car in UP

Eight passengers in the car were killed on the spot

Virat Kohli becomes fastest cricketer to score 12,000 ODI runs, beats Tendulkar's record

Virat Kohli becomes fastest cricketer to score 12,000 ODI runs, beats Tendulkar's record

Kohli reached the milestone during the third and final match...

Cities

View All